Business context and reporting period
The supplied filing is Helius Medical Technologies, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2022—not a filing for Solana Co. Helius develops non-implanted neurological technologies; its PoNS device began U.S. commercial sales in April 2022 and has been sold in Canada since 2019. Unless noted otherwise, financial amounts below are in U.S. dollars and in thousands.
Financial performance and liquidity
| Metric | Three months ended June 30, 2022 | Three months ended June 30, 2021 | Six months ended June 30, 2022 | Six months ended June 30, 2021 |
|---|---|---|---|---|
| Revenue | $119 | $71 | $309 | $155 |
| Gross profit / margin | $31 / 26.1% | $4 / 5.6% | $97 / 31.4% | $72 / 46.5% |
| Operating loss | $(3,430) | $(6,166) | $(7,994) | $(9,667) |
| Net loss | $(3,810) | $(5,981) | $(8,156) | $(9,343) |
| Loss per share, basic and diluted | $(0.97) | $(2.58) | $(2.11) | $(4.29) |
- Q2 revenue included $56 from Canada and $63 from the U.S.; first-half product sales were $239 in Canada and $63 in the U.S. Revenue remains small relative to operating expenses.
- First-half operating cash use was $8,346, versus $6,690 in the prior-year period. Investing cash use was $6; financing provided $620. Cash fell to $3,273 from $11,005 at December 31, 2021.
- At June 30, current assets were $5,064 and current liabilities $1,777, yielding working capital of $3,287. Total liabilities were $2,044, including $135 of operating lease liabilities; the filing reports no borrowings.
- On August 9, 2022, after quarter-end, the company completed a public offering and received approximately $16.4 million in net proceeds. Management said existing resources, including these proceeds, were expected to fund operations into the third quarter of 2023, with additional financing needed thereafter.
Material changes versus the prior comparable period
- Q2 revenue rose $48, primarily reflecting U.S. product sales, while first-half revenue increased $154 year over year.
- Q2 operating loss narrowed by $2,736, largely as selling, general and administrative expense fell $2,283, including a substantial reduction in stock-based compensation. First-half operating loss narrowed by $1,673; first-half R&D expense was broadly flat.
- Gross margin improved in Q2 but declined for the six-month period, as product costs increased faster than sales over the first half.
- Foreign exchange shifted to a loss: $380 in Q2 2022 versus a $185 gain in Q2 2021; first-half foreign exchange loss was $163 versus a $324 gain.
- Operating cash use increased by $1,656 year over year, and first-half financing proceeds were far below the prior-year period’s $10,834.
Outlook, commentary, and risks
- The filing states that substantial doubt existed about Helius’s ability to continue as a going concern within one year after filing, given its losses, cash needs, and limited revenue. Management’s runway estimate incorporates the subsequent offering; future financing is still required, with no assurance it will be available on acceptable terms.
- Management expects continued operating losses and plans to use capital for U.S. commercialization, manufacturing, clinical trials, and working capital. It also expects additional funding will be needed for a planned stroke clinical trial.
- PoNS is not covered by CMS or reimbursed by U.S. third-party payors. The company was pursuing reimbursement and unique HCPCS codes and expected self-pay patients to be a principal sales source before broader coverage; it estimated broad payer coverage could take at least 24 months.
- The company launched a reduced-price Patient Therapy Access Program in June 2022, expected to run through December 31, 2022. Participants must agree not to submit reimbursement claims to third-party payors.
- COVID-19-related labor shortages and supply-chain disruptions had delayed production; further manufacturing constraints, higher costs, and demand shortfalls remained possible. The filing also cites inflation, competition for talent, clinical and regulatory uncertainty, and reliance on third-party manufacturers and distributors.
- The August offering included 18.56 million common shares, pre-funded warrants for 5.44 million shares (exercised at closing), and warrants for 36 million shares at $0.75, exercisable upon issuance and expiring in five years. Offering-related performance criteria triggered vesting of performance stock options; the company expected $1.2 million of additional stock-based compensation in Q3 2022.
- The company reported no material legal proceedings and said disclosure controls were effective. It identified potential Nasdaq minimum-bid-price compliance risk; the filing noted the share price had been below $1.00 since August 5, 2022.
Important facts for investors to verify
- Confirm the issuer and filing identity: this source is Helius Medical Technologies, Inc., not Solana Co.
- Track cash burn, commercial sales, and whether the stated runway through Q3 2023 remains achievable.
- Assess the timing and likelihood of CMS, commercial-insurer, and HCPCS reimbursement, alongside U.S. patient demand and PTAP sales.
- Verify manufacturing capacity, supply reliability, and progress in resolving production delays.
- Evaluate dilution and potential warrant exercises following the August 2022 offering, and the effect of Nasdaq listing requirements.